- PR Newswire•8 hours agoNew Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016
"These analyses continue to shape the clinical evidence for Repatha and help to advance our understanding of its potential to benefit patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. Researchers looking at the "Efficacy of evolocumab in patients across ESC/EAS CV risk subgroups," categorized a total of 2,532 patients from three, 12-week Phase 3 studies by the four ESC/European Atherosclerotic Society (EAS) risk criteria (very high, high, moderate and low). The analysis showed that treatment with Repatha 140 mg every two weeks or 420 mg monthly consistently reduced levels of LDL-C and other lipids from baseline to the mean of weeks 10 and 12 across all risk categories compared to placebo or ezetimibe controls.
- Motley Fool•2 days ago
PCSK-9 inhibitors lowered LDL-C by roughly 60% in clinical trials, but do their costs far outweigh their benefits?
- Benzinga•3 days ago
After a placid summer seldom interrupted by news of note, word comes down from Wyoming on Friday as Fed Chair Janet Yellen speaks. Speculation centers around what Yellen could say about potential rate ...
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||172.10 - 172.50|
|52wk Range||130.09 - 176.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.63|
|Avg Vol (3m)||2,907,642|
|Dividend & Yield||4.00 (2.33%)|